Loss of JUNB/AP-1 promotes invasive prostate cancer

Cell Death and Differentiation

Volumn 22, Issue 4, 2015, Pages 574-582

  Thomsen, M K ^a,c   Bakiri, L ^a   Hasenfuss, S C ^a,d   Wu, H ^a   Morente, M ^b   Wagner, E F ^a  

^a BBVA University Institute for Economic and Social Analysis University of Alcalá   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c AARHUS UNIVERSITY   (Denmark)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; JUNB PROTEIN, MOUSE; MESSENGER RNA; S100A8 PROTEIN, MOUSE; S100A9 PROTEIN, MOUSE; SPP1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CELL POPULATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; EPIGENETICS; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SENESCENCE; STROMA; TUMOR INVASION; AGING; ANIMAL; C57BL MOUSE; DISEASE COURSE; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

AGING; ANIMALS; CALGRANULIN A; CALGRANULIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; OSTEOPONTIN; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84925535470     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.213     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
2. Liu Y, Hegde P, Zhang F, Hampton G, Jia S. Prostate cancer - a biomarker perspective. Front Endocrinol (Lausanne) 2012; 3: 72.
3. Parisotto M, Metzger D. Genetically engineered mouse models of prostate cancer. Mol Oncol 2013; 7: 190-205.
4. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-273.
5. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
6. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730.
7. Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL et al. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 2006; 25: 7212-7223.
8. Edwards J, Krishna NS, Mukherjee R, Bartlett JM. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 2004; 204: 153-158.
9. Hubner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T et al. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci USA 2012; 109: 12046-12051.
10. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008; 68: 2132-2144.
11. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007; 11: 555-569.
12. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001; 104: 21-32.
13. Konishi N, Shimada K, Nakamura M, Ishida E, Ota I, Tanaka N et al. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Clin Cancer Res 2008; 14: 4408-4416.
14. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.
15. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
16. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-4506.
17. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005; 65: 5730-5739.
18. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000; 19: 2056-2068.
19. Passegue E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 2000; 19: 2969-2979.
20. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005; 11: 5146-5152.
21. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437: 369-375.
22. Schonthaler HB, Guinea-Viniegra J,Wculek SK, Ruppen I, Ximenez-Embun P, Guio-Carrion A et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity 2013; 39: 1171-1181.
23. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 2008; 105: 10525-10530.
24. Hasenfuss SC, Bakiri L, Thomsen MK, Hamacher R, Wagner EF. Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology 2014; 59: 261-273.
25. Leow CC, Wang XD, Gao WQ. Novel method of generating prostate-specific Cre-LoxP gene switching via intraductal delivery of adenovirus. Prostate 2005; 65: 1-9.
26. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102: 678-684.
27. Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 2010; 6: e1000995.
28. Francis JC, Thomsen MK, Taketo MM, Swain A. beta-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet 2013; 9: e1003180.
29. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 2010; 70: 979-987.
30. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
31. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013; 123: 4918-4922.
32. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-565.
33. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503-511.
34. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 2002; 99: 1455-1460.
35. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal 2009; 2: ra44.
36. Yogev O, Anzi S, Inoue K, Shaulian E. Induction of transcriptionally active Jun proteins regulates drug-induced senescence. J Biol Chem 2006; 281: 34475-34483.
37. Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL et al. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell 2009; 15: 341-352.
38. Vartanian R, Masri J, Martin J, Cloninger C, Holmes B, Artinian N et al. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation. Mol Cancer Res 2011; 9: 115-130.
39. Kenner L, Hoebertz A, Beil FT, Keon N, Karreth F, Eferl R et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol 2004; 164: 613-623.
40. Behrens A, Sibilia M, David JP, Mohle-Steinlein U, Tronche F, Schutz G et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBOJ 2002; 21: 1782-1790.